173 related articles for article (PubMed ID: 12850192)
21. A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells.
Kanamori Y; Kigawa J; Minagawa Y; Irie T; Oishi T; Shimada M; Takahashi M; Nakamura T; Sato K; Terakawa N
Eur J Cancer; 1998 Oct; 34(11):1802-6. PubMed ID: 9893672
[TBL] [Abstract][Full Text] [Related]
22. Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Miettinen S; Ylikomi T
Anticancer Drugs; 2009 Aug; 20(7):589-600. PubMed ID: 19491654
[TBL] [Abstract][Full Text] [Related]
23. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
24. New p53-based anti-cancer therapeutic strategies.
Wiman KG
Med Oncol; 1998 Dec; 15(4):222-8. PubMed ID: 9951684
[TBL] [Abstract][Full Text] [Related]
25. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
26. Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC.
Kim CK; Choi EJ; Choi SH; Park JS; Haider KH; Ahn WS
Gynecol Oncol; 2003 Aug; 90(2):265-72. PubMed ID: 12893186
[TBL] [Abstract][Full Text] [Related]
27. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells.
Sasaki H; Sheng Y; Kotsuji F; Tsang BK
Cancer Res; 2000 Oct; 60(20):5659-66. PubMed ID: 11059757
[TBL] [Abstract][Full Text] [Related]
28. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
29. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic.
Zhang WW; Li L; Li D; Liu J; Li X; Li W; Xu X; Zhang MJ; Chandler LA; Lin H; Hu A; Xu W; Lam DM
Hum Gene Ther; 2018 Feb; 29(2):160-179. PubMed ID: 29338444
[TBL] [Abstract][Full Text] [Related]
30. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
31. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
32. Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of Coxsackie-adenovirus receptors in human lung cancer cells.
Tango Y; Taki M; Shirakiya Y; Ohtani S; Tokunaga N; Tsunemitsu Y; Kagawa S; Tani T; Tanaka N; Fujiwara T
Cancer Sci; 2004 May; 95(5):459-63. PubMed ID: 15132776
[TBL] [Abstract][Full Text] [Related]
33. p53 Plays a Key Role in the Apoptosis of Human Ovarian Cancer Cells Induced by Adenovirus-Mediated CRM197.
Dai L; Pan Q; Peng Y; Huang S; Liu J; Chen T; Wang X; Chen D; Wang J; Zhu Y; Wang H; Liu Y; Ou Y; Yu X; Cao K
Hum Gene Ther; 2018 Aug; 29(8):916-926. PubMed ID: 29620944
[TBL] [Abstract][Full Text] [Related]
34. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
[TBL] [Abstract][Full Text] [Related]
35. p53 tumor suppressor gene therapy for cancer.
Roth JA; Swisher SG; Meyn RE
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):148-54. PubMed ID: 10550840
[TBL] [Abstract][Full Text] [Related]
36. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
37. Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer.
Wen SF; Mahavni V; Quijano E; Shinoda J; Grace M; Musco-Hobkinson ML; Yang TY; Chen Y; Runnenbaum I; Horowitz J; Maneval D; Hutchins B; Buller R
Cancer Gene Ther; 2003 Mar; 10(3):224-38. PubMed ID: 12637944
[TBL] [Abstract][Full Text] [Related]
38. The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.
Grace MJ; Xie L; Musco ML; Cui S; Gurnani M; DiGiacomo R; Chang A; Indelicato S; Syed J; Johnson R; Nielsen LL
Am J Pathol; 1999 Dec; 155(6):1869-78. PubMed ID: 10595917
[TBL] [Abstract][Full Text] [Related]
39. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
40. Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
Bar JK; Harłozińska A; Popiela A; Noga L
Tumour Biol; 2001; 22(2):83-91. PubMed ID: 11125280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
